Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD

por Hermans, Michel P.
Publicado 2010

802 A retrospective study: rapid removal of biofilm and necrosis with a hygroscopic chemical debriding compound

por Hermans, Michel H
Publicado 2022

Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes

por Lurquin, Fabian, Gohy, Sophie, Hermans, Michel P., Preumont, Vanessa
Publicado 2023

A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Patients

por Binet, Quentin, Loumaye, Audrey, Hermans, Michel P, Lanthier, Nicolas
Publicado 2023

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males

por Hermans, Michel P, Ahn, Sylvie A, Rousseau, Michel F
Publicado 2010

The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females

por Hermans, Michel P, Ahn, Sylvie A, Rousseau, Michel F
Publicado 2012

Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B(100) in patients with T2DM

por Hermans, Michel P, Ahn, Sylvie A, Rousseau, Michel F
Publicado 2013

Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids

por Hermans, Michel P, Ahn, Sylvie A, Rousseau, Michel F
Publicado 2014

The mixed benefit of low lipoprotein(a) in type 2 diabetes

por Hermans, Michel P., Ahn, Sylvie A., Rousseau, Michel F.
Publicado 2017

Distinction of cardiometabolic profiles among people ≥75 years with type 2 diabetes: a latent profile analysis

por CHRISTIAENS, Antoine, HERMANS, Michel P., BOLAND, Benoit, HENRARD, Séverine
Publicado 2019

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?

por Fruchart, Jean-Charles, Hermans, Michel P., Fruchart-Najib, Jamila
Publicado 2020

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

por Fruchart, Jean-Charles, Hermans, Michel P., Fruchart-Najib, Jamila, Kodama, Tatsuhiko
Publicado 2021

Non-HDL-cholesterol as valid surrogate to apolipoprotein B(100 )measurement in diabetes: Discriminant Ratio and unbiased equivalence

por Hermans, Michel P, Sacks, Frank M, Ahn, Sylvie A, Rousseau, Michel F
Publicado 2011

Unsuspected diabetic ketoacidosis after myocardial infarction in a patient treated with SGLT2 inhibitor increased length of stay in the hospital: how can it be prevented? A case re...

por Oriot, Philippe, Hermans, Michel P, Beauloye, Christophe, Rogghe, Pierre-Arnaud, Noel, Sophie, Paternotte, Emmanuelle
Publicado 2023

Relationship between waist circumference, visceral fat and metabolic syndrome in a Congolese community: further research is still to be undertaken

por Katchunga, Philippe Bianga, Hermans, Michel, Bamuleke, Bertrand Akonkwa, Katoto, Patrick Cimusa, Kabinda, Jeff Maotela
Publicado 2013

Bioelectrical impedance outperforms waist circumference for predicting cardiometabolic risk in Congolese hypertensive subjects: a cross-sectional study

por Katchunga, Philippe Bianga, Bapolisi, Achile Mwira, M’Buyamba-Kabangu, Jean-René, Hermans, Michel P
Publicado 2015

A Retrospective Health Economic Analysis of a Stable Hypochlorous Acid Preserved Wound Cleanser Versus 0.9% Saline Solution as Instillation for Negative-Pressure Wound Therapy in S...

por Gallagher, Kathy E, Alberto, Emily C, Mallow, Peter J, Hermans, Michel H, Cardenas, Luis
Publicado 2022

Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus

por Nobels, Frank, Debacker, Noëmi, Brotons, Carlos, Elisaf, Moses, Hermans, Michel P, Michel, Georges, Muls, Erik
Publicado 2011

Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes: The OPTIMISE randomized, controlled trial

por Hermans, Michel P., Elisaf, Moses, Michel, Georges, Muls, Erik, Nobels, Frank, Vandenberghe, Hans, Brotons, Carlos
Publicado 2013

Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies

por Hermans, Michel P., Bouenizabila, Evariste, Amoussou-guenou, Daniel K., Ahn, Sylvie A., Rousseau, Michel F.
Publicado 2015